The global ophthalmic diagnostic devices market reached USD 16.2 billion in 2025 and is set to grow to USD 30.3 billion by 2034, a compound annual growth rate of 7.21%, according to a new report from Contrive Datum Insights; revenue is expected to reach USD 17.37 billion in 2026 before compounding steadily across the following eight years.
The market covers instruments used to examine, image, and measure the structures and function of the eye for the detection and monitoring of cataract, glaucoma, retinal disease, and refractive error. It includes imaging systems such as optical coherence tomography scanners, fundus cameras, and ultrasound imaging systems; functional testing equipment such as perimeters and wavefront aberrometers; and basic clinical examination tools including tonometers, slit lamps, and phoropters. Hospital ophthalmology departments, independent eye clinics, optometry practices, and academic or research laboratories purchase these devices for both routine screening and pre-surgical evaluation.
The report identifies expansion of retinal disease screening programs for diabetic retinopathy and age-related macular degeneration as the largest single contributor to growth over the forecast period, rating its impact high. Product lines tied to this expansion move ahead of the market's 7.21% average: optical biometry systems compound at 13.02% a year, taking their share of revenue from 4% in 2025 to 6.5% by 2034 and their value from USD 0.65 billion to USD 1.97 billion.
By product, optical coherence tomography scanners hold the largest share of 2025 revenue at 24%, worth USD 3.89 billion, and extend that lead to 28% by 2034. Fundus cameras, the second-largest line at 15% of 2025 revenue, grow at only 6.36%, below the market average. By function, imaging-based diagnostic devices led in 2025 with 45% of revenue (USD 7.29 billion). Purchase-based capital acquisition accounted for 78% of 2025 revenue (USD 12.64 billion), while the smaller subscription-based model grows fastest at 13.49%. Cataract applications led 2025 revenue at 32% (USD 5.18 billion); vitreo-retinal disorders grow fastest among applications, at 8.41%. Hospitals and eye clinics generated 82% of 2025 revenue (USD 13.28 billion), and academic and research laboratories, though a smaller buyer group, grow fastest at 8.46%.
North America generated 34% of 2025 revenue, USD 5.51 billion, and is projected to reach USD 9.39 billion by 2034. The United States alone accounts for USD 4.68 billion of 2025 revenue, 28.9% of the global total. Asia Pacific's share rises over the forecast period, from 29% in 2025 to 33% in 2034, with revenue climbing from USD 4.7 billion to USD 10 billion. The Middle East and Africa stays the smallest region throughout, moving from 6.5% of 2025 revenue to 7% by 2034.
The base-case forecast of USD 30.3 billion by 2034 depends on screening programs and hospital purchasing continuing on their current trajectory. If public and private screening programs for diabetic retinopathy and glaucoma expand faster and hospitals adopt AI-assisted imaging analytics sooner, pulling forward purchases of OCT and biometry systems across established and mid-tier hospital markets alike, 2034 revenue could reach USD 33.33 billion. Slower reimbursement approval for diagnostic imaging procedures and longer hospital capital-budget cycles would work in the other direction, delaying equipment replacement and new-site installations in markets where public health systems fund most ophthalmology purchases, and holding 2034 revenue to USD 27.27 billion.
The full report segments the market by product, function, procurement/ownership model, application, and end use, with revenue and growth rates for every line from 2020 to 2034, plus country-level detail across all five regions, the competitive landscape, and methodology. It is delivered as a PDF; a free sample is available on request.